Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MDS
MCID: MYL009
MIFTS: 70

Myelodysplastic Syndrome (MDS)

Categories: Blood diseases, Genetic diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Myelodysplastic Syndrome

About this section

MalaCards integrated aliases for Myelodysplastic Syndrome:

Name: Myelodysplastic Syndrome 57 12 75 37 29 13 6 15 38 40 73
Myelodysplastic Syndromes 38 76 53 55 43 44
Myelodysplasia 53 29 6
Mds 57 53 75
Myelodysplastic Syndrome, Somatic 57 13
Myelodysplastic Syndrome, Susceptibility to, Included 57
Myelodysplastic Syndrome, Susceptibility to 57
Myelodysplastic Syndrome Included 57

Characteristics:

HPO:

32
myelodysplastic syndrome:
Inheritance somatic mutation


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Blood diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

OMIM 57 614286
Disease Ontology 12 DOID:0050908
MeSH 44 D009190
MedGen 42 C3463824
KEGG 37 H01481
ICD10 33 D46
Sources

Summaries for Myelodysplastic Syndrome

About this section
MedlinePlus : 43 Your bone marrow is the spongy tissue inside some of your bones, such as your hip and thigh bones. It contains immature cells, called stem cells. The stem cells can develop into the red blood cells that carry oxygen through your body, the white blood cells that fight infections, and the platelets that help with blood clotting. If you have a myelodysplastic syndrome, the stem cells do not mature into healthy blood cells. Many of them die in the bone marrow. This means that you do not have enough healthy cells, which can lead to infection, anemia, or easy bleeding. Myelodysplastic syndromes often do not cause early symptoms and are sometimes found during a routine blood test. If you have symptoms, they may include Shortness of breath Weakness or feeling tired Skin that is paler than usual Easy bruising or bleeding Pinpoint spots under the skin caused by bleeding Fever or frequent infections Myelodysplastic syndromes are rare. People at higher risk are over 60, have had chemotherapy or radiation therapy, or have been exposed to certain chemicals. Treatment options include transfusions, drug therapy, chemotherapy, and blood or bone marrow stem cell transplants. NIH: National Cancer Institute

MalaCards based summary : Myelodysplastic Syndrome, also known as myelodysplastic syndromes, is related to myelodysplastic myeloproliferative cancer and juvenile myelomonocytic leukemia. An important gene associated with Myelodysplastic Syndrome is GATA2 (GATA Binding Protein 2), and among its related pathways/superpathways are Spliceosome and Signaling pathways regulating pluripotency of stem cells. The drugs Decitabine and Azacitidine have been mentioned in the context of this disorder. Affiliated tissues include Placenta and Umbilical Cord, and related phenotypes are myelodysplasia and neoplasm

Disease Ontology : 12 A bone marrow cancer that is characterized by under production of white blood cells, red blood cells and platelets.

NIH Rare Diseases : 53 Myelodysplastic syndromes (MDS) are a group of blood disorders characterized by abnormal development of blood cells within the bone marrow. People with MDS have abnormally low blood cell levels (low blood counts). Signs and symptoms may include dizziness, fatigue, weakness, shortness of breath, bruising and bleeding, frequent infections, and headaches. In some people with MDS, the condition progresses to bone marrow failure or develops into acute leukemia. MDS develops when a cell with a mutation replicates, and the resulting copies begin to predominate in the bone marrow and suppress healthy stem cells. The mutation may result from a genetic predisposition, or from injury to the DNA caused by an exposure such as chemotherapy or radiation. In many people with MDS there is no obvious exposure or cause. Standard treatments for people with MDS and decreased blood counts are constantly changing. The main components of care include transfusions of the types of cells that are deficient and treatment of infections. A stem cell transplant may cure the disease, but it is only indicated in selected cases. 

OMIM : 57 Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematologic stem cell disorders characterized by ineffective hematopoiesis resulting in low blood counts, most commonly anemia, and a risk of progression to acute myeloid leukemia (AML; 601626). Blood smears and bone marrow biopsies show dysplastic changes in myeloid cells, with abnormal proliferation and differentiation of 1 or more lineages (erythroid, myeloid, megakaryocytic). MDS can be subdivided into several categories based on morphologic characteristics, such as low-grade refractory anemia (RA) or high-grade refractory anemia with excess blasts (RAEB). Bone marrow biopsies of some patients show ringed sideroblasts (RARS), which reflects abnormal iron staining in mitochondria surrounding the nucleus of erythrocyte progenitors (summary by Delhommeau et al., 2009 and Papaemmanuil et al., 2011). (614286)

UniProtKB/Swiss-Prot : 75 Myelodysplastic syndrome: A heterogeneous group of closely related clonal hematopoietic disorders. All are characterized by a hypercellular or hypocellular bone marrow with impaired morphology and maturation, dysplasia of the myeloid, megakaryocytic and/or erythroid lineages, and peripheral blood cytopenias resulting from ineffective blood cell production. Included diseases are: refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS); chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative disease. MDS is considered a premalignant condition in a subgroup of patients that often progresses to acute myeloid leukemia (AML).

Wikipedia : 76 Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow... more...

Sources

Related Diseases for Myelodysplastic Syndrome

About this section

Diseases related to Myelodysplastic Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 767)
# Related Disease Score Top Affiliating Genes
1 myelodysplastic myeloproliferative cancer 33.1 ASXL1 HRAS NRAS SETBP1 TET2
2 juvenile myelomonocytic leukemia 33.0 DNMT3A NRAS SETBP1 TET2
3 aplastic anemia 32.8 ASXL1 GATA2 NRAS TET2 TP53
4 myeloid leukemia 32.1 DNMT3A GATA2 HRAS IDH1 NRAS TET2
5 leukemia, acute myeloid 31.8 ASXL1 DNMT3A GATA2 HRAS IDH1 IDH2
6 chronic myelomonocytic leukemia 31.5 ASXL1 DNMT3A SETBP1 TET2 U2AF1
7 myelofibrosis 30.8 ASXL1 HRAS IDH1 IDH2 MEG3 TET2
8 myeloma, multiple 30.7 HRAS IDH1 IDH2 MEG3 NRAS TP53
9 essential thrombocythemia 30.7 ASXL1 IDH1 IDH2 TET2 TP53
10 chronic leukemia 30.6 ASXL1 SETBP1 TET2
11 leukemia, chronic lymphocytic 2 30.6 HRAS MIR34A NRAS TP53
12 acquired idiopathic sideroblastic anemia 30.6 SF3B1 TET2
13 leukemia, chronic myeloid 30.4 GATA2 HRAS MEG3 MIR10A NRAS SETBP1
14 acute erythroid leukemia 30.3 GATA2 TP53
15 cytogenetically normal acute myeloid leukemia 30.3 IDH1 IDH2
16 oligodendroglioma 30.2 IDH1 IDH2 TP53
17 melanoma 30.0 MEG3 MIR127 MIR34A NRAS TP53
18 suppression of tumorigenicity 12 30.0 HRAS IDH1 TP53
19 glioma 29.7 IDH1 IDH2 MEG3 MIR34A TP53
20 kidney cancer 29.6 MEG3 MIR378A TP53
21 hepatocellular carcinoma 29.3 HRAS IDH1 IDH2 MEG3 MIR127 MIR34A
22 bladder cancer 29.2 HRAS MEG3 MIR10A MIR127 TP53
23 pancreatic cancer 29.0 HRAS MEG3 MIR10A MIR127 MIR34A TP53
24 myelodysplastic syndrome with excess blasts 12.5
25 chromosome 5q deletion syndrome 12.3
26 acute myeloid leukemia and myelodysplastic syndromes related to radiation 12.2
27 unclassified myelodysplastic syndrome 12.2
28 therapy related acute myeloid leukemia and myelodysplastic syndrome 12.1
29 acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent 12.1
30 acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor 12.1
31 myelodysplasia, immunodeficiency, facial dysmorphism, short stature, and psychomotor delay 12.0
32 muscular dystrophy 11.9
33 miller-dieker lissencephaly syndrome 11.8
34 bone marrow failure syndrome 1 11.8
35 epidermolysa bullosa simplex with muscular dystrophy 11.8
36 alpha-thalassemia myelodysplasia syndrome 11.7
37 lymphedema, primary, with myelodysplasia 11.5
38 shwachman-diamond syndrome 1 11.4
39 muscular dystrophy-dystroglycanopathy , type a, 1 11.4
40 dystonia 11, myoclonic 11.3
41 thiamine-responsive megaloblastic anemia syndrome 11.3
42 myeloproliferative neoplasm 11.3
43 epidermolysis bullosa simplex with muscular dystrophy 11.3
44 deafness-lymphedema-leukemia syndrome 11.3
45 sideroblastic anemia 11.3
46 dyskeratosis congenita 11.3
47 pelger-huet anomaly 11.3
48 sea-blue histiocyte disease 11.3
49 neutropenia, severe congenital, 3, autosomal recessive 11.3
50 diamond-blackfan anemia 11.3

Graphical network of the top 20 diseases related to Myelodysplastic Syndrome:



Diseases related to Myelodysplastic Syndrome
Sources

Symptoms & Phenotypes for Myelodysplastic Syndrome

About this section

Clinical features from OMIM:

614286

Human phenotypes related to Myelodysplastic Syndrome:

32
# Description HPO Frequency HPO Source Accession
1 myelodysplasia 32 HP:0002863

MGI Mouse Phenotypes related to Myelodysplastic Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.1 ASXL1 HRAS IDH2 NRAS TET2 TP53
Sources

Drugs & Therapeutics for Myelodysplastic Syndrome

About this section

Drugs for Myelodysplastic Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 614)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Decitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2353-33-5 451668
2
Azacitidine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 320-67-2 9444
3
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
4
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
5
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
6 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
8
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7439-89-6 23925
9
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58957-92-9 42890
10
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
11
Fludarabine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
12
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
13
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 24356-66-9 32326 21704
14
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
15
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
16
Deferasirox Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 201530-41-8 5493381
17
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 171228-49-2 147912
18
Micafungin Approved, Investigational Phase 4,Phase 2 235114-32-6 3081921 477468
19
Radium Ra 223 dichloride Approved, Investigational Phase 4,Phase 1,Phase 2 444811-40-9
20
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 1406-16-2
21
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 2 67-97-0 5280795 6221
22
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2 50-14-6 5280793
23 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
26 Cyclosporins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
33 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
34 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
35 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
37 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
38 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Epoetin alfa Phase 4,Phase 2,Phase 3,Phase 1 113427-24-0
45 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
46 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
49 Vitamins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
50 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 1990)
# Name Status NCT ID Phase Drugs
1 A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome Unknown status NCT02013102 Phase 4 Decitabine Injection
2 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
3 Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia Unknown status NCT01997372 Phase 4 ATG
4 Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells（Umbilical Cord Derived） Unknown status NCT02218437 Phase 4 MSC+ATG
5 Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome Completed NCT00488436 Phase 4 Antithymocyte globulin;Cyclosporine
6 Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) Completed NCT01201811 Phase 4 Azacitidine
7 Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload Completed NCT00564941 Phase 4 deferasirox
8 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
9 SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia Completed NCT00487448 Phase 4 Fludarabine;Cytarabine;G-CSF;Idarubicin
10 Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load Completed NCT00452660 Phase 4 Exjade
11 Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload Completed NCT00481143 Phase 4 ICL670/Deferasirox
12 Biological Predictive Factors of Response to ESA in Low Risk MDS Patients Completed NCT03598582 Phase 4 Epoetin Zeta
13 This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload. Completed NCT01250951 Phase 4 Deferasirox
14 Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload Completed NCT00673608 Phase 4 deferasirox
15 Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4 Busulfan;Fludarabine
16 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
17 An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study) Completed NCT01736540 Phase 4
18 Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed NCT00867932 Phase 4 Eculizumab
19 A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS) Recruiting NCT02145026 Phase 4 Epoetin beta
20 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4 posaconazole
21 Radium-223 Dichloride Long-term Follow-up Program Recruiting NCT02312960 Phase 4
22 King's Invasive Aspergillosis Study II Active, not recruiting NCT02875743 Phase 4 Posaconazole
23 A Rollover Study to Provide Continued Treatment With Eltrombopag Active, not recruiting NCT01957176 Phase 4 ELT
24 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Enrolling by invitation NCT03176849 Phase 4
25 Myelodysplastic Syndrome--CDA-2 Hematological Improvement National Affirmation Study Not yet recruiting NCT03335943 Phase 4 CDA-2 (Cell Differentiation Agent 2)
26 Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) Not yet recruiting NCT01339988 Phase 4 Busulfan/Cyclophosphamide
27 To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS. Terminated NCT01011283 Phase 4 decitabine;azacitidine
28 Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study Terminated NCT01326845 Phase 4 Deferasirox
29 Transfusion Effects in Myelodysplastic Patients: Limiting Exposure Withdrawn NCT00202371 Phase 4
30 The Effect of Combination Ultra Q10 and L-carnitine on the Course of Myelodysplastic Syndrome Unknown status NCT02042482 Phase 2, Phase 3
31 Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes Unknown status NCT01196715 Phase 3 Darbepoetin alpha;Filgrastim
32 Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS) Unknown status NCT00234143 Phase 2, Phase 3 Darbepoetin
33 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Unknown status NCT00002926 Phase 3 cytarabine;etoposide;idarubicin
34 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3 decitabine
35 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
36 Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
37 Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Unknown status NCT01809392 Phase 2, Phase 3 decitabine
38 Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS Unknown status NCT01417767 Phase 2, Phase 3 CHG regimen;5-aza-deoxycytidine
39 Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) Unknown status NCT01295710 Phase 3
40 Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00003602 Phase 3 cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
41 Prospective Study of Patients With Thrombocytopenia Following HSCT Unknown status NCT02487563 Phase 3 decitabine;rhTPO
42 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
43 Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Unknown status NCT01217723 Phase 3
44 The Impact of Red Cell Age on Product Utilization in the Chronically Transfused Outpatient Population Unknown status NCT02393508 Phase 3
45 Bowel Preparation and Prokinetics in Capsule Endoscopy Unknown status NCT00275184 Phase 3 Senna;Citramag powder;Metoclopramide
46 Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T Unknown status NCT00209833 Phase 2, Phase 3 Cytarabine;Idarubicin;Etoposide;Fludarabine;G-CSF;Daunorubicine
47 An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome Completed NCT01751867 Phase 3 Decitabine at 15 mg/m2;Decitabine at 20 mg/m2
48 An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes Completed NCT01381809 Phase 3 Group 2: Placebo;Group 1: Epoetin alfa
49 A Study of LY2157299 in Participants With Myelodysplastic Syndromes Completed NCT02008318 Phase 2, Phase 3 LY2157299;Placebo
50 An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS) Completed NCT01186939 Phase 3 Azacitidine

Search NIH Clinical Center for Myelodysplastic Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Myelodysplastic Syndrome cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Myelodysplastic Syndrome:
Co-infusion of umbilical cord blood and haploidentical CD34+ cells for hematological diseases
Hemacord�, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Hematopoietic stem cells for treatment of hematologic malignancies
NiCord�, umbilical cord blood-derived stem/progenitor cells for hemotological diseases
StemEx�, umbilical cord blood stem/progenitor cells for hematological diseases
Umbilical cord/placenta-derived mesenchymal stem cells for myelodysplastic syndrome
Embryonic/Adult Cultured Cells Related to Myelodysplastic Syndrome:
Peripheral blood-derived hematopoietic stem cells
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD�) PMIDs: 9828244
Bone marrow-derived hematopoietic stem cells
Umbilical cord blood-derived stem cells (NiCord) PMIDs: 22198152
Umbilical cord blood stem/progenitor cells (Stemex) PMIDs: 18209724
Umbilical cord-derived mesenchymal stem cells (family)
Placenta-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: myelodysplastic syndromes

Sources

Genetic Tests for Myelodysplastic Syndrome

About this section

Genetic tests related to Myelodysplastic Syndrome:

# Genetic test Affiliating Genes
1 Myelodysplastic Syndrome 29 ASXL1 GATA2 SF3B1 TET2
2 Myelodysplasia 29
Sources

Anatomical Context for Myelodysplastic Syndrome

About this section

MalaCards organs/tissues related to Myelodysplastic Syndrome:

41
Myeloid, Bone, Bone Marrow, T Cells, Testes, B Cells, Nk Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Myelodysplastic Syndrome:
# Tissue Anatomical CompartmentCell Relevance
1 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate
2 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
3 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
Sources

Publications for Myelodysplastic Syndrome

About this section

Articles related to Myelodysplastic Syndrome:

(show top 50) (show all 2956)
# Title Authors Year
1
Red Blood Cell Alloimmunization in Korean Patients With Myelodysplastic Syndrome and Liver Cirrhosis. ( 30430787 )
2019
2
Prognostic significance of monosomal karyotype in myelodysplastic syndrome: a meta-analysis. ( 30129389 )
2019
3
TET2 rs2454206, TET2 rs12498609 and ASXL1 rs3746609 single nucleotide polymorphisms in patients with myelodysplastic syndromes. ( 30454965 )
2019
4
Usefulness of tocilizumab for treating rheumatoid arthritis with myelodysplastic syndrome: A case report and literature review. ( 29924032 )
2018
5
A decade of progress in myelodysplastic syndrome with chromosome 5q deletion. ( 29445113 )
2018
6
Utility of a Single-Tube, Six-Color Flow Cytometry Panel for the Diagnosis of Myelodysplastic Syndrome: Experience of a Tertiary Care Centre in India. ( 29951175 )
2018
7
A Case of Pyoderma Gangrenosum with Myelodysplastic Syndrome. ( 29853768 )
2018
8
Editorial Comment to Therapy-related acute myeloid leukemia and myelodysplastic syndrome among refractory germ cell tumor patients. ( 29869384 )
2018
9
Remission of relapsing polychondritis after successful treatment of myelodysplastic syndrome with azacitidine: a case and review of the literature. ( 29715182 )
2018
10
Harnessing the PD-1 Pathway in Myelodysplastic Syndrome. ( 29394170 )
2018
11
Evaluation of the utility of peripheral blood vs bone marrow in karyotype and fluorescence in situ hybridization for myelodysplastic syndrome diagnosis. ( 29893006 )
2018
12
Association of red cell distribution width with clinical outcomes in myelodysplastic syndrome. ( 29433052 )
2018
13
L-leucine increases translation of RPS14 and LARP1 in erythroblasts from del(5q) myelodysplastic syndrome patients. ( 29903759 )
2018
14
Azacitidine-associated pleuropericardial effusion in myelodysplastic syndrome: A case report. ( 29933727 )
2018
15
Del(5q) myelodysplastic syndrome combined with pure red cell aplasia. ( 29963514 )
2018
16
High Incidence of Gastrointestinal Ulceration and Cytogenetic Aberration of Trisomy 8 as Typical Features of BehAset's Disease Associated with Myelodysplastic Syndrome: A Series of 16 Consecutive Chinese Patients from the Shanghai BehAset's Disease Database and Comparison with the Literature. ( 29854799 )
2018
17
Successful treatment with ustekinumab and vacuum-assisted closure therapy in recalcitrant myelodysplastic syndrome-associated pyoderma gangrenosum: case report and literature review. ( 29851121 )
2018
18
Iron overload impairs normal hematopoietic stem and progenitor cells through reactive oxygen species and shortens survival in myelodysplastic syndrome mice. ( 29903757 )
2018
19
Acute liver failure due to liver parenchymal infiltration with acute myelogenous leukaemia in a patient with myelodysplastic syndrome. ( 29954762 )
2018
20
Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome. ( 29449681 )
2018
21
NSG-S mice for acute myeloid leukemia, yes. For myelodysplastic syndrome, no. ( 29866886 )
2018
22
Leptin-deficient obesity prolongs survival in a murine model of myelodysplastic syndrome. ( 29371326 )
2018
23
Therapy-related acute myeloid leukemia and myelodysplastic syndrome among refractory germ cell tumor patients. ( 29752743 )
2018
24
Successful Treatment of Syndrome of Inappropriate Antidiuretic Hormone Secretion Associated with Neuro-Sweet Disease in Myelodysplastic Syndrome. ( 29225251 )
2018
25
CD41 immune staining of micromegakaryocytes improves the diagnosis of myelodysplastic syndrome and differentiation from pancytopenia. ( 29353154 )
2018
26
p300 suppresses leukemia development in NUP98-HOXD13 driven myelodysplastic syndrome. ( 29928471 )
2018
27
Constitutional<i>SAMD9L</i>mutations cause familial myelodysplastic syndrome and transient monosomy 7. ( 29217778 )
2018
28
Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies. ( 29936305 )
2018
29
Myelodysplastic syndrome presenting as a BehAset's-like disease with aortitis. ( 29545422 )
2018
30
Successful Treatment of Hemophagocytic Lymphohistiocytosis Associated with Low-risk Myelodysplastic Syndrome by Azacitidine. ( 29780114 )
2018
31
Wilms' Tumor 1 Gene Expression Using a Standardized European LeukemiaNet-Certified Assay Compared to Other Methods for Detection of Minimal Residual Disease in Myelodysplastic Syndrome and Acute Myelogenous Leukemia after Allogeneic Blood Stem Cell Transplantation. ( 29753838 )
2018
32
The role of T2*-weighted gradient echo in the diagnosis of tumefactive intrahepatic extramedullary hematopoiesis in myelodysplastic syndrome and diffuse hepatic iron overload: a case report and review of the literature. ( 29332607 )
2018
33
Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34<sup>+</sup>Selected and Unmodified Hematopoietic Stem Cell Transplantation. ( 29325829 )
2018
34
Corrigendum to 'CD41 immune staining of micromegakaryocytes improves the diagnosis of myelodysplastic syndrome and differentiation from pancytopenia' [leukemia research. 2018; 66: 15-19]. ( 29673488 )
2018
35
Eight-ball hyphema after laser iridotomy in a patient with undiagnosed hypocellular myelodysplastic syndrome. ( 29950905 )
2018
36
Triple primary malignancies of surface osteosarcoma of jaw, myelodysplastic syndrome and colorectal cancer as a second primary cancer detected by PET2-[<sup>18</sup>F]-fluoro-2-deoxy-D-glucose positron emission tomography: A case report. ( 29928362 )
2018
37
Leukocyte Cell Population Data Provide Clues for Myelodysplastic Syndrome in a 79-Year-old Male. ( 29398825 )
2018
38
Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). ( 29067707 )
2018
39
Discriminating myelodysplastic syndrome and other myeloid malignancies from non-clonal disorders by multiparametric analysis of automated cell data. ( 29378171 )
2018
40
Evaluation of Parameters Related to the Probability of Leukemic Progression in Patients With Lower-Risk Myelodysplastic Syndrome. ( 29807802 )
2018
41
Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia. ( 29435331 )
2018
42
Growth factor independence 1b. A key player in the genesis and maintenance of acute myeloid leukaemia and myelodysplastic syndrome. ( 29326122 )
2018
43
Partial tandem duplication of KMT2A (MLL) may predict a subset of myelodysplastic syndrome with unique characteristics and poor outcome. ( 29351983 )
2018
44
Catheter-Related Trichosporon asahii Bloodstream Infection in a Neutropenic Patient with Myelodysplastic Syndrome. ( 29968981 )
2018
45
Clinical Features and Outcomes of 666 Cases with Therapy-Related Myelodysplastic Syndrome (t-MDS). ( 29398804 )
2018
46
The Impact of Iron Overload in Patients with Acute Leukemia and Myelodysplastic Syndrome on Hepatic and Endocrine functions. ( 29633728 )
2018
47
Interferon-α salvage treatment is effective for patients with acute leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation. ( 29656333 )
2018
48
Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: A randomized study. ( 29746955 )
2018
49
Acquired α-thalassemia associated with myelodysplastic syndromes. ( 30442749 )
2018
50
Circulating exosomal microRNAs in acquired aplastic anemia and myelodysplastic syndromes. ( 29674506 )
2018
Sources

Variations for Myelodysplastic Syndrome

About this section

UniProtKB/Swiss-Prot genetic disease variations for Myelodysplastic Syndrome:

75
# Symbol AA change Variation ID SNP ID
1 GATA2 p.Thr354Met VAR_066406 rs387906631
2 SETBP1 p.Asp868Asn VAR_063807 rs267607042
3 SETBP1 p.Gly870Ser VAR_063809 rs267607040
4 SETBP1 p.Ser869Asn VAR_069852
5 SETBP1 p.Thr873Arg VAR_069857
6 U2AF1 p.Ser34Phe VAR_079637 rs371769427
7 U2AF1 p.Ser34Tyr VAR_079638 rs371769427
8 U2AF1 p.Gln157Arg VAR_079639 rs371246226

ClinVar genetic disease variations for Myelodysplastic Syndrome:

6 (show top 50) (show all 85)
# Gene Variation Type Significance SNP ID Assembly Location
1 MT-TL1 m.3242G> A single nucleotide variant Pathogenic rs193303018 GRCh37 Chromosome MT, 3242: 3242
2 MT-TL1 m.3242G> A single nucleotide variant Pathogenic rs193303018 GRCh38 Chromosome MT, 3242: 3242
3 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
4 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
5 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
6 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
7 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
8 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
9 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
10 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
11 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
12 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
13 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
14 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh38 Chromosome 1, 114716124: 114716124
15 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
16 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs121434596 GRCh38 Chromosome 1, 114716123: 114716123
17 IDH2 NM_002168.3(IDH2): c.419G> A (p.Arg140Gln) single nucleotide variant Pathogenic rs121913502 GRCh37 Chromosome 15, 90631934: 90631934
18 IDH2 NM_002168.3(IDH2): c.419G> A (p.Arg140Gln) single nucleotide variant Pathogenic rs121913502 GRCh38 Chromosome 15, 90088702: 90088702
19 GATA2 NM_032638.4(GATA2): c.1061C> T (p.Thr354Met) single nucleotide variant Pathogenic rs387906631 GRCh37 Chromosome 3, 128200744: 128200744
20 GATA2 NM_032638.4(GATA2): c.1061C> T (p.Thr354Met) single nucleotide variant Pathogenic rs387906631 GRCh38 Chromosome 3, 128481901: 128481901
21 GATA2 GATA2, 3-BP DEL, 1063ACA deletion risk factor
22 NRAS NM_002524.4(NRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913237 GRCh37 Chromosome 1, 115258747: 115258747
23 NRAS NM_002524.4(NRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913237 GRCh38 Chromosome 1, 114716126: 114716126
24 NRAS NM_002524.4(NRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs121913250 GRCh37 Chromosome 1, 115258748: 115258748
25 NRAS NM_002524.4(NRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs121913250 GRCh38 Chromosome 1, 114716127: 114716127
26 NRAS NM_002524.4(NRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913250 GRCh37 Chromosome 1, 115258748: 115258748
27 NRAS NM_002524.4(NRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913250 GRCh38 Chromosome 1, 114716127: 114716127
28 NRAS NM_002524.4(NRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913237 GRCh37 Chromosome 1, 115258747: 115258747
29 NRAS NM_002524.4(NRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913237 GRCh38 Chromosome 1, 114716126: 114716126
30 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
31 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh37 Chromosome 2, 209113112: 209113112
32 NRAS NM_002524.4(NRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913250 GRCh37 Chromosome 1, 115258748: 115258748
33 NRAS NM_002524.4(NRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913250 GRCh38 Chromosome 1, 114716127: 114716127
34 GNB1 NM_002074.4(GNB1): c.239T> C (p.Ile80Thr) single nucleotide variant Pathogenic rs752746786 GRCh37 Chromosome 1, 1737942: 1737942
35 GNB1 NM_002074.4(GNB1): c.239T> C (p.Ile80Thr) single nucleotide variant Pathogenic rs752746786 GRCh38 Chromosome 1, 1806503: 1806503
36 NRAS NM_002524.4(NRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs121913237 GRCh37 Chromosome 1, 115258747: 115258747
37 NRAS NM_002524.4(NRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs121913237 GRCh38 Chromosome 1, 114716126: 114716126
38 SF3B1 NM_012433.3(SF3B1): c.1998G> T (p.Lys666Asn) single nucleotide variant Pathogenic rs377023736 GRCh37 Chromosome 2, 198267359: 198267359
39 SF3B1 NM_012433.3(SF3B1): c.1998G> T (p.Lys666Asn) single nucleotide variant Pathogenic rs377023736 GRCh38 Chromosome 2, 197402635: 197402635
40 TP53 NM_000546.5(TP53): c.743G> T (p.Arg248Leu) single nucleotide variant Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
41 TP53 NM_000546.5(TP53): c.743G> T (p.Arg248Leu) single nucleotide variant Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
42 TP53 NM_000546.5(TP53): c.743G> C (p.Arg248Pro) single nucleotide variant Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
43 TP53 NM_000546.5(TP53): c.743G> C (p.Arg248Pro) single nucleotide variant Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
44 NRAS NM_002524.4(NRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
45 NRAS NM_002524.4(NRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh38 Chromosome 1, 114716123: 114716123
46 DNMT3A NM_175629.2(DNMT3A): c.2645G> C (p.Arg882Pro) single nucleotide variant Pathogenic/Likely pathogenic rs147001633 GRCh37 Chromosome 2, 25457242: 25457242
47 DNMT3A NM_175629.2(DNMT3A): c.2645G> C (p.Arg882Pro) single nucleotide variant Pathogenic/Likely pathogenic rs147001633 GRCh38 Chromosome 2, 25234373: 25234373
48 DNMT3A NM_175629.2(DNMT3A): c.2645G> A (p.Arg882His) single nucleotide variant Conflicting interpretations of pathogenicity rs147001633 GRCh37 Chromosome 2, 25457242: 25457242
49 DNMT3A NM_175629.2(DNMT3A): c.2645G> A (p.Arg882His) single nucleotide variant Conflicting interpretations of pathogenicity rs147001633 GRCh38 Chromosome 2, 25234373: 25234373
50 DNMT3A NM_175629.2(DNMT3A): c.2644C> T (p.Arg882Cys) single nucleotide variant Pathogenic/Likely pathogenic rs377577594 GRCh37 Chromosome 2, 25457243: 25457243

Copy number variations for Myelodysplastic Syndrome from CNVD:

7 (show top 50) (show all 82)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 18423 1 14554092 29473750 Deletion Myelodysplastic syndrome
2 33240 1 43803475 43820135 Mutation MPL Myelodysplastic syndrome
3 40833 10 133929972 135293404 Duplication Myelodysplastic syndrome
4 44880 10 64500000 70600000 Loss Myelodysplastic syndrome
5 50727 11 119076986 119178859 Mutation CBL Myelodysplastic syndrome
6 51205 11 123900000 135006516 Gain Myelodysplastic syndrome
7 51499 11 127052052 133951370 Duplication Myelodysplastic syndrome
8 52451 11 1733191 2138300 Duplication Myelodysplastic syndrome
9 62482 12 10889756 25048970 Deletion Myelodysplastic syndrome
10 65983 12 239401 32382344 Deletion Myelodysplastic syndrome
11 72801 12 8689944 10025942 Deletion Myelodysplastic syndrome
12 97766 16 13109256 13949702 Deletion Myelodysplastic syndrome
13 108396 17 202809 18798804 Deletion Myelodysplastic syndrome
14 108397 17 202809 22129948 Deletion Myelodysplastic syndrome
15 109400 17 25800000 31800000 Gain Myelodysplastic syndrome
16 110294 17 31800000 38100000 Gain Myelodysplastic syndrome
17 116723 17 69689099 78513583 Duplication Myelodysplastic syndrome
18 116794 17 69987407 78623230 Deletion Myelodysplastic syndrome
19 118116 17 7571720 7590868 Mutation P53 Myelodysplastic syndrome
20 121808 18 47174275 49624685 Deletion Myelodysplastic syndrome
21 124116 19 1 59128983 Deletion Myelodysplastic syndrome
22 128856 19 43400000 45200000 Deletion Myelodysplastic syndrome
23 131185 19 53600000 59128983 Amplification Myelodysplastic syndrome
24 140406 2 197400000 204900000 Loss Myelodysplastic syndrome
25 152708 20 32473920 33605249 Deletion Myelodysplastic syndrome
26 153104 20 34400000 49800000 Deletion Myelodysplastic syndrome
27 153115 20 34507776 56709287 Deletion Myelodysplastic syndrome
28 153160 20 34853717 51702925 Deletion Myelodysplastic syndrome
29 158211 21 30500000 46944323 Microdeletion RUNX1 Myelodysplastic syndrome
30 160489 22 15438133 31661481 Triplication Myelodysplastic syndrome
31 168487 3 130292954 199251329 Duplication Myelodysplastic syndrome
32 180470 4 106067032 106200960 Mutation TET2 Myelodysplastic syndrome
33 181366 4 120601325 121421102 Deletion MAD2L1 Myelodysplastic syndrome
34 181367 4 120601325 121421102 Deletion PDE5A Myelodysplastic syndrome
35 181368 4 120601325 121421102 Deletion SAR1P3 Myelodysplastic syndrome
36 188218 4 60577199 61810493 Deletion Myelodysplastic syndrome
37 188320 4 62191591 126940390 Deletion Myelodysplastic syndrome
38 188506 4 65578799 66861924 Deletion EPHA5 Myelodysplastic syndrome
39 189909 4 80195990 82530576 Deletion ANTXR2 Myelodysplastic syndrome
40 189910 4 80195990 82530576 Deletion ARD1B Myelodysplastic syndrome
41 189911 4 80195990 82530576 Deletion BMP3 Myelodysplastic syndrome
42 189912 4 80195990 82530576 Deletion C4orf22 Myelodysplastic syndrome
43 189913 4 80195990 82530576 Deletion FGF5 Myelodysplastic syndrome
44 189914 4 80195990 82530576 Deletion GK2 Myelodysplastic syndrome
45 189915 4 80195990 82530576 Deletion PRDM8 Myelodysplastic syndrome
46 189916 4 80195990 82530576 Deletion PRKG2 Myelodysplastic syndrome
47 191854 5 102760027 157708888 Deletion Myelodysplastic syndrome
48 193154 5 125503105 161513040 Deletion Myelodysplastic syndrome
49 200025 5 48400000 180915260 Deletion GLRA1 Myelodysplastic syndrome
50 200026 5 48400000 180915260 Deletion SH3TC2 Myelodysplastic syndrome
Sources

Expression for Myelodysplastic Syndrome

About this section
Search GEO for disease gene expression data for Myelodysplastic Syndrome.
Sources

Pathways for Myelodysplastic Syndrome

About this section

Pathways related to Myelodysplastic Syndrome according to KEGG:

37
# Name Kegg Source Accession
1 Spliceosome hsa03040
2 Signaling pathways regulating pluripotency of stem cells hsa04550

Pathways related to Myelodysplastic Syndrome according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Proteoglycans in cancer 37
11.86 HRAS MIR10A NRAS TP53
2
Glioblastoma Multiforme 64
11.7 HRAS NRAS TP53
3
MicroRNAs in cancer 37
11.58 DNMT3A HRAS MIR10A MIR34A NRAS TP53
4
Bladder cancer 37 1
11.41 HRAS NRAS TP53
5
Mitophagy - animal 37
11.31 HRAS NRAS TP53
6
Central carbon metabolism in cancer 37
11.27 HRAS IDH1 NRAS TP53
7
Transcription_Transcription factor Tubby signaling pathways 22
11.05 HRAS NRAS TP53
8
Nongenotropic Androgen signaling 1
10.75 GNB1 HRAS
9
p38MAPK events 66
10.55 HRAS NRAS
10
LncRNA-mediated mechanisms of therapeutic resistance 1
10.48 MEG3 TP53
11
Cytosine methylation 1
Show member pathways
 10.25 IDH1 IDH2 TET2
Sources

GO Terms for Myelodysplastic Syndrome

About this section

Cellular components related to Myelodysplastic Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 micro-ribonucleoprotein complex GO:0035068 9.02 MEG3 MIR10A MIR127 MIR34A MIR378A

Biological processes related to Myelodysplastic Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.77 MEG3 MIR10A MIR127 MIR34A MIR378A
2 cellular response to hypoxia GO:0071456 9.46 DNMT3A GNB1 MIR34A TP53
3 positive regulation of cellular senescence GO:2000774 9.4 MIR10A MIR34A
4 NADP metabolic process GO:0006739 9.32 IDH1 IDH2
5 isocitrate metabolic process GO:0006102 9.26 IDH1 IDH2
6 glyoxylate cycle GO:0006097 8.96 IDH1 IDH2
7 Ras protein signal transduction GO:0007265 8.92 GNB1 HRAS NRAS TP53

Molecular functions related to Myelodysplastic Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH1 IDH2
2 isocitrate dehydrogenase activity GO:0004448 8.62 IDH1 IDH2
Sources

Sources for Myelodysplastic Syndrome

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....